Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
The 2019/20 Community Pharmacy Assurance Framework (CPAF) screening questionnaire will soon be available for completion from Monday 3rd June 2019 until Sunday 30th June 2019. The process asks all NHS community pharmacy contractors to complete a short screening questionnaire consisting of 10 active questions which should be answered; NHS England will then select a small...
Supply Update Merck Sharp & Dohme Limited (MSD) are still experiencing intermittent supply issues which are expected to continue until early June with the following products: Sinemet 25mg/250mg 10×10 tablets. Sinemet 12.5mg/50mg 9×10 tablets. Sinemet CR 50mg/200mg 6×10 tablets. Sinemet plus 10mg/100mg 10×10 tablets. MSD have confirmed the following Sinemet products should now be available:...
In March, PSNC announced that market-entry applications were to move online as PCSE confirmed a new approach for pharmacy applications which will see the replacement of multiple paper forms with one single online application, accessible via PCSE Online. PSNC has been and will continue to work with PCSE on the development of the market-entry online...
PSNC and the NHS Business Services Authority (NHSBSA) will be holding a Schedule of Payments webinar on Tuesday 11th June at 7.30pm. The webinar will aim to help community pharmacy contractors to better understand their FP34 Schedule of Payments. Webinar Details When is it? Tuesday 11th June at 7.30pm. Who should attend Every community pharmacy contractor...
Are you an exceptional strategic thinking individual who can provide innovative solutions to support and develop community pharmacy? If so, we may have the ideal job opportunity for you. Kent Local Pharmaceutical Committee (LPC) is looking to recruit a new Chief Executive Officer. This exciting key leadership full time role offers the perfect opportunity for an...
Further to a news story published earlier this year, NHS England has received further reports from the same hotel chain of faxes being received from pharmacies, which were not intended for the hotel. The hotel chain in question (fax number 0330 333 2812), which has been receiving faxes containing anonymised prescriptions, has a very similar...
Drug alert number: EL (19) A/12 Date issued: 13th May 2019 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 pharmacy level medicines recall, to be actioned within 48 hours, for certain batches of co-amoxiclav 125mg/31.25mg/5ml powder for oral suspension and 250mg/62.5mg/5ml powder for oral suspension. Sandoz Limited is recalling the...
Colgate-Palmolive has advised that the distribution of their promotional materials for the NHS England children’s oral health campaign has been delayed; therefore community pharmacy contractors will now receive these materials week commencing 13th May 2019. The NHS England community pharmacy oral health campaign is due to start on Monday 13th May 2019, which means contractors...
The House of Lords Select Committee on the Rural Economy recently published a report which has recommended that the Government take steps to improve pharmaceutical services in rural areas. Following a call for evidence, PSNC, along with Community Pharmacy Wales, submitted evidence to the inquiry, advocating greater utilisation of community pharmacies to deliver healthcare needs...
Date issued: 7th May 2019 CLDA Number: CLDA (19) A/03 Macopharma has informed MHRA that it is recalling certain batches of intravenous infusion bags as a precaution. This is due to the detection of metal particles in two infusion bags. No incidents have been reported in the UK. Action Pharmacy teams are asked to quarantine...
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
While an urgent EU safety review evaluates reports of serious cardiovascular events and immune-mediated reactions, including autoimmune hepatitis, the use of alemtuzumab (Lemtrada) has been restricted and strengthened requirements have been introduced to monitor vital signs and liver function before and during treatment. All patients on alemtuzumab for multiple sclerosis should be alerted to these risks and what to do if symptoms occur.
Following observation in a clinical study of an increased risk of pulmonary embolism and overall mortality with tofacitinib 10 mg twice-daily in rheumatoid arthritis, a safety review has started and new contraindications introduced. The 10 mg twice-daily dose of tofacitinib (authorised for ulcerative colitis) must not be used in patients at high risk of pulmonary embolism.
Maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy has been associated with skeletal adverse effects and hypocalcaemia and hypermagnesemia in neonates. If use of magnesium sulfate in pregnancy is prolonged or repeated, consider monitoring of neonates for abnormal calcium and magnesium levels and skeletal adverse effects.
2018 saw a fall in reporting of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme from key reporter groups, including GPs, pharmacists, and hospital doctors. Every Yellow Card report counts, and a few minutes taken by you or your patient to report can make a lifetime of difference for others – don’t delay, report today!
Letters were sent about alemtuzumab (Lemtrada), Selenase (sodium selenite pentahydrate), and Erelzi▼ (etanercept).
An alert was issued about Moift Mover 180/205 mobile hoist and Molift Air ceiling hoist.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
How to apply for, update and cancel licences for the manufacture, import and wholesale of human and veterinary medicines.
Department of Health and MHRA register of licensed manufacturing sites - manufacturer specials (human) (MS) and manufacturer specials authorisation (veterinary) (MANSA) only.
Department of Health and Social Care and MHRA register of licensed wholesale distribution sites (human and veterinary).
Parallel import licenses granted in April 2019
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Marketing authorisations granted in April 2019
List of field safety notices (FSNs) from medical device manufacturers from 7 to 10 May 2019.
Sandoz Ltd. have been notified of a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle.
Product defect recall alert for Norfenicol 300mg/ml solution for injection (Vm 02000/4316) by Norbrook Laboratories Ltd.
Web services, such as the Special Imports System, and the telephone service will be unavailable due to essential electrical maintenance.
UK global approach to tackling the threat of antimicrobial resistance (AMR) gets UN recognition.
Summary of responses to survey of vets on issues relating to the use and disposal of CDs to better understand the issues they face in complying with their legal obligations.
Product defect recall alert for Tylan 200mg/ml Solution for injection - Vm 00006/4098 by Elanco UK AH Ltd
Web services, such as the Special Imports System are unavailable due to an unscheduled power shut-down.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
Marketing Authorisations Veterinary Information Service (MAVIS) Hub edition 110.
Report of the ten products for which most Special Import and Special Treatment Certificates (SIC and STC) have been issued by VMD in the UK.
Residues of veterinary medicines in food 2019 surveillance results.
Residues of veterinary medicines in food 2018 surveillance results.
Monthly reporting against VMD published standards up to 31 March 2019.
How to apply for approval for a suitably qualified person (SQP) retailer premises to sell or supply animal medicines.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
Guidance for the pharmaceutical industry on who can be a Marketing Authorisation Holder, named distributor, or local representative of veterinary medicines.
Guidance on the application process for an ATC or ATC-S to carry out veterinary field trials of a medicinal product.
How to make sure an application relating to an authorisation for a veterinary medicine is complete and will pass validation.
Guidance for the pharmaceutical industry on applying for a marketing authorisation for parallel import (MAPI).
Guidance on applying to renew a marketing authorisation (MA) for a veterinary medicine.
Guidance and application form to apply for a Marketing Authorisation (MA) to place a veterinary medicine on the market, or to expire an MA.
The new indication will benefit approximately 2,100 patients.
The researchers retrieved data on 143.7 million people aged 20 to 49 years from 20 European countries.
The approval of these combination therapies “Marks a significant milestone for patients with multiple myeloma in Europe".
The drug was initially approved by the FDA in 1994 for adults and is a type of heparin.
The winners of the PharmaTimes International Clinical Researcher of the Year have been announced, find out who emerged victorious in the 2019 competition.
The programme is to be launched in a £75 million state-of-the-art global centre of expertise in anti-evolution therapies in London.
SpaceOAR hydrogel acts as a spacer, reducing the amount of radiation that can pass through the prostate and damage the rectum during treatment.
The companies will begin discussions with the US Food and Drug Administration (FDA) to prepare for regulatory submission.
The company's Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.
The worrying rise bucks decades of progress that has seen annual deaths from heart and circulatory disease half since the 1960s.
The recommendation is for infants, children and adults with 5q spinal muscular atrophy and will be available through a scheme known as a Managed Access Agreement.
The drug is the only VEGF inhibitor approved with two dosing options for diabetic retinopathy.
The guideline states that thyroid hormones should not be routinely offered to adults with subclinical hypothyroidism.
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
Unique in the industry, the PharmaTimes Communications Team of the Year competition gives communications professionals the opportunity to demonstrate their skills in a live environment, developing a strategic and tactical pitch in response to a fictional, but realistic challenge.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
